Neoleukin (@neoleukin) 's Twitter Profile
Neoleukin

@neoleukin

In December 2023, the previously announced merger between Neurogene Inc and Neoleukin Therapeutics (NGNE) was completed. Visit @NeurogeneInc for more info.

ID: 1083082019020500992

linkhttp://www.neurogene.com calendar_today09-01-2019 19:24:10

73 Tweet

435 Takipçi

18 Takip Edilen

Neoleukin (@neoleukin) 's Twitter Profile Photo

CEO Jonathan Drachman is presenting at the HC Wainwright Global Investment Conference...investor.neoleukin.com/news-releases/…

CEO Jonathan Drachman is presenting at the HC Wainwright Global Investment Conference...investor.neoleukin.com/news-releases/…
Neoleukin (@neoleukin) 's Twitter Profile Photo

Pleased to announce that Bill Arthur, Ph.D., has joined Neoleukin as VP and Head of Research. investor.neoleukin.com/news-releases/…

Pleased to announce that Bill Arthur, Ph.D., has joined Neoleukin as VP and Head of Research. investor.neoleukin.com/news-releases/…
Neoleukin (@neoleukin) 's Twitter Profile Photo

Oral Presentation at @IDWeek2021 of Data Demonstrating NL-CVX-1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Concern... investor.neoleukin.com/news-releases/…

Oral Presentation at @IDWeek2021 of Data Demonstrating NL-CVX-1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Concern... investor.neoleukin.com/news-releases/…
Neoleukin (@neoleukin) 's Twitter Profile Photo

Neoleukin will present at the upcoming Stifel and Piper Sandler Virtual Healthcare Conferences. investor.neoleukin.com/news-releases/…

Neoleukin will present at the upcoming Stifel and Piper Sandler Virtual Healthcare Conferences. investor.neoleukin.com/news-releases/…
Neoleukin (@neoleukin) 's Twitter Profile Photo

Preclinical data on Neoleukin's #denovoprotein NL-201 at #sitc2021. Visit the SITC website or read more here:investor.neoleukin.com/news-releases/…

Preclinical data on Neoleukin's #denovoprotein NL-201 at #sitc2021. Visit the SITC website or read more here:investor.neoleukin.com/news-releases/…
Neoleukin (@neoleukin) 's Twitter Profile Photo

Neoleukin joined leading healthcare and life science companies this morning for the Nasdaq opening bell ceremony to kick off day one of the J.P. Morgan conference.livestream.com/accounts/27896…

Neoleukin joined leading healthcare and life science companies this morning for the <a href="/Nasdaq/">Nasdaq</a> opening bell ceremony to kick off day one of the <a href="/jpmorgan/">J.P. Morgan</a> conference.livestream.com/accounts/27896…
Neoleukin (@neoleukin) 's Twitter Profile Photo

Coming up next week, Neoleukin will participate in Guggenheim Healthcare Talks 2022 Oncology Day with a presentation on Thursday. investor.neoleukin.com/news-releases/…

Coming up next week, Neoleukin will participate in Guggenheim Healthcare Talks 2022 Oncology Day with a presentation on Thursday. investor.neoleukin.com/news-releases/…
Neoleukin (@neoleukin) 's Twitter Profile Photo

Neoleukin will conduct a 2021 Financial Results Conference Call & Webcast on March 1, 2022... more info here: investor.neoleukin.com/news-releases/…

Neoleukin will conduct a 2021 Financial Results Conference Call &amp; Webcast on March 1, 2022... more info here: investor.neoleukin.com/news-releases/…
Neoleukin (@neoleukin) 's Twitter Profile Photo

Today Neoleukin announced 2021 year end financial results and corporate update. Visit our website for press release and earnings call webcast link: lnkd.in/gDgs2DrS

Today Neoleukin announced 2021 year end financial results and corporate update. Visit our website for press release and earnings call webcast link: lnkd.in/gDgs2DrS
Neoleukin (@neoleukin) 's Twitter Profile Photo

Preclinical data on Neoleukin's NL-201 - including antitumor activity in B-cell lymphoma and synergistic activity in combination - highlighted in multiple presentations AACR Annual Meeting... #AACR22 #denovoprotein investor.neoleukin.com/news-releases/…

Preclinical data on Neoleukin's NL-201 - including antitumor activity in B-cell lymphoma and synergistic activity in combination - highlighted in multiple presentations <a href="/AACR/">AACR</a> Annual Meeting... #AACR22 #denovoprotein investor.neoleukin.com/news-releases/…
Neoleukin (@neoleukin) 's Twitter Profile Photo

The Neoleukin team - Justin Huard, Ryan Swanson and Jonathan Drachman - connecting at our NL-201 poster presentation during the AACR annual meeting #AACR22 #denovoprotein

The Neoleukin team - Justin Huard, Ryan Swanson and <a href="/jdrachman/">Jonathan Drachman</a> - connecting at our NL-201 poster presentation during the <a href="/AACR/">AACR</a> annual meeting #AACR22 #denovoprotein
Neoleukin (@neoleukin) 's Twitter Profile Photo

Today Neoleukin announced First Quarter 2022 financial results and corporate update. Please visit our website for full press release: investor.neoleukin.com/news-releases/…

Today Neoleukin announced First Quarter 2022 financial results and corporate update. Please visit our website for full press release: investor.neoleukin.com/news-releases/…
Neoleukin (@neoleukin) 's Twitter Profile Photo

Pleased to announce treatment of first patient in the combination arm of our Phase 1 trial evaluating NL-201 with KEYTRUDA® investor.neoleukin.com/news-releases/…

Pleased to announce treatment of first patient in the combination arm of our Phase 1 trial evaluating NL-201 with KEYTRUDA® investor.neoleukin.com/news-releases/…
Neoleukin (@neoleukin) 's Twitter Profile Photo

Today Neoleukin Therapeutics announced third quarter 2022 financial results and corporate update. Please visit our website for full release: investor.neoleukin.com/news-releases/…

Today Neoleukin Therapeutics announced third quarter 2022 financial results and corporate update. Please visit our website for full release: investor.neoleukin.com/news-releases/…
Neoleukin (@neoleukin) 's Twitter Profile Photo

Neoleukin presents data on NEO-TRA1, a precision-tuned agonist of the IL-2 receptor beta and gamma subunits, in an oral presentation at the American Society of Hematology (ASH) Annual Meeting. #ASH2022 investor.neoleukin.com/news-releases/…

Neoleukin presents data on NEO-TRA1, a precision-tuned  agonist of the IL-2 receptor beta and gamma subunits, in an oral presentation at the American Society of Hematology (ASH) Annual Meeting. #ASH2022  investor.neoleukin.com/news-releases/…
Neoleukin (@neoleukin) 's Twitter Profile Photo

Neoleukin provides strategic update and announces restructuring and leadership transition... investor.neoleukin.com/news-releases/…

Neoleukin provides strategic update and announces restructuring and leadership transition... investor.neoleukin.com/news-releases/…
Neoleukin (@neoleukin) 's Twitter Profile Photo

The previously announced merger between Neoleukin Therapeutics and Neurogene Inc is now complete. Please follow Neurogene Inc. for news and updates. Learn more here: bwnews.pr/3v0ilVM